Selected article for: "drug efficacy safety and efficacy safety"
Author: Israel Junior Borges do Nascimento; Donal P O'Mathuna; Thilo Caspar von Groote; Hebatullah Mohamed Abdulazeem; Ishanka Weerasekara; Ana Marusic; Livia Puljak; Vinicius Tassoni Civile; Irena Zakarija-Grkovic; Tina Poklepovic Pericic; Alvaro Nagib Atallah; Santino Filoso; Nicola Luigi Bragazzi; Milena Soriano Marcolino
Title: Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews
  • Document date: 2020_4_22
    • ID: e7o4iub7_50
    Snippet: Pharmacological and non-pharmacological interventions (supportive therapies) used in the treatment of patients with COVID-19 were reported in five reviews [16, 17, 23, 24, 27] . Most reviews were descriptive, as the original studies did not assess the impact of therapies. Antivirals have been used empirically for COVID-19 treatment with the most commonly used being protease inhibitors (lopinavir, ritonavir, darunavir), nucleoside reverse transcri.....
    Document: Pharmacological and non-pharmacological interventions (supportive therapies) used in the treatment of patients with COVID-19 were reported in five reviews [16, 17, 23, 24, 27] . Most reviews were descriptive, as the original studies did not assess the impact of therapies. Antivirals have been used empirically for COVID-19 treatment with the most commonly used being protease inhibitors (lopinavir, ritonavir, darunavir), nucleoside reverse transcriptase inhibitor (tenofovir), nucleotide analog (remdesivir, galidesivir, ganciclovir), and neuraminidase inhibitors (oseltamivir). Umifenovir, a membrane fusion inhibitor, was investigated in several studies [16, 24] . Possible supportive interventions analyzed were different types of oxygen supplementation and breathing support (invasive or non-invasive ventilation). Use of antibiotics, both empirically and to treat secondary pneumonia, was reported in some studies. One review specifically assessed evidence on the efficacy and safety of the anti-malaria drug chloroquine [17] . It identified 23 ongoing trials investigating the potential of chloroquine as a therapeutic option for COVID-19, but no verifiable clinical outcomes data. Use of mesenchymal stem cells, antifungals and glucocorticoids were seldom described.

    Search related documents:
    Co phrase search for related documents
    • antiviral empirically treatment and empirically treatment: 1, 2
    • breathing support and invasive non invasive ventilation: 1
    • breathing support and invasive non invasive ventilation breathing support: 1
    • chloroquine potential and clinical outcome: 1, 2
    • chloroquine potential and drug chloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • clinical outcome and different type: 1, 2, 3, 4, 5, 6, 7
    • clinical outcome and drug chloroquine: 1, 2
    • clinical outcome and empirically treatment: 1, 2
    • clinical outcome and invasive non invasive ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • drug chloroquine and fusion inhibitor: 1
    • fusion inhibitor and membrane fusion inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14